Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227)

Authors not listed

Masonic Cancer Center, University of Minnesota · 2007

Abstract

RATIONALE: Bortezomib may stop the growth of solid tumors by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with gemcitabine may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib and gemcitabine in treating older patients with advanced solid tumors.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-01 MST

Cite this

APA
Anonymous. (2007). Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227). <em>Masonic Cancer Center, University of Minnesota</em>. https://clinicaltrials.gov/study/NCT00620295
Vancouver
Anonymous. Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227). Masonic Cancer Center, University of Minnesota. 2007.
BibTeX
@misc{anon2007PhaseI, title = {Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227)}, author = {Anonymous}, journal = {Masonic Cancer Center, University of Minnesota}, year = {2007}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings